News >

Immunotherapy Takes Hold in Frontline Advanced Nonsquamous NSCLC

Caroline Seymour
Published: Monday, Nov 18, 2019

Jyoti D. Patel, MD, FASCO, professor of medicine and director of Thoracic Oncology at the University of Chicago Medicine

Jyoti D. Patel, MD, FASCO

Frontline immunotherapy has shown tremendous benefit in patients with advanced nonsquamous non–small cell lung cancer (NSCLC), but it should only be given in the absence of a driver mutation, according to Jyoti D. Patel, MD, FASCO.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication